Search clinical trials for: Moderate to Severe Plaque Psoriasis

Total 478743 results

Janssen-Cilag G.m.b.H

Completed

A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (POLARIS)

Psoriasis

Germany
LEO Pharma

Completed

A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis

Psoriasis Vulgaris

Germany
Bausch Health Americas, Inc.

Terminated

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis (AMAGINE-2)

Moderate to Severe Plaque Psoriasis

United States, Austria, France, Poland, Australia, Czechia, Canada, Hungary, Portugal, Spain, Netherlands
Bausch Health Americas, Inc.

Terminated

Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-1)

Psoriasis

United States, Germany, Poland, Switzerland, France, Canada
Bausch Health Americas, Inc.

Terminated

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3)

Plaque Psoriasis

United States, Belgium, Italy, Hungary, Poland, Australia, France, Greece, Russian Federation, Latvia, Canada
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Plaque Psoriasis

China, Thailand, Philippines, Turkey, Hungary, Malaysia
Akeso
Akeso Tiancheng, Inc

Completed

A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Celgene

Terminated

Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis

Healthy Volunteers | Parapsoriasis

United States
AbbVie
Boehringer Ingelheim

Completed

Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment

Plaque Psoriasis

Germany
AbbVie
Boehringer Ingelheim

Completed

BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

Psoriasis
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis (ECLIPSE)

Psoriasis

United States, Germany, France, Hungary, Czechia, Canada, Spain, Australia, Poland
Eli Lilly and Company

Completed

Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis (UNCOVER-A)

Plaque Psoriasis

United States, Puerto Rico
Eli Lilly and Company
Incyte Corporation

Completed

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

Skin Diseases | Psoriasis | Skin Diseases, Papulosquamous

Canada, Japan, United States, Puerto Rico
Novartis Pharmaceuticals

Completed

A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis. (PROSE)

Plaque Psoriasis

Germany, United Kingdom, Belgium, Czechia, Estonia, Italy, France, Israel, Spain, Bulgaria, Lithuania, Portugal, Poland, Romania, Latvia, Greece, Slovakia
Eli Lilly and Company

Completed

A Study in Participants With Moderate to Severe Psoriasis

Psoriasis

United States, Denmark
AbbVie

Completed

A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy

Psoriasis

Germany
Novartis Pharmaceuticals

Completed

Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis (GAIN)

Moderate to Severe Plaque-type Psoriasis

Germany
MetrioPharm AG
Bioskin GmbH

Completed

Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis

Psoriasis

Poland, Germany
AbbVie
Boehringer Ingelheim

Completed

BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
UCB Pharma

Completed

Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis

Psoriasis

France, Germany
Novartis Pharmaceuticals

Completed

A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME) (SUPREME)

Plaque Type Psorisis

Italy
Diamant Thaci

Withdrawn

Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients (Itch)

Moderate to Severe Plaque Psoriasis

Germany
Novartis Pharmaceuticals

Completed

Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis (IPSI-PSO)

Psoriasis

France
Pfizer

Completed

A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis

Psoriasis

Korea, Republic of, Taiwan, China
Amgen

Completed

Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis

Psoriasis

Australia, Canada, Hungary
Pfizer

Completed

Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis

Chronic Plaque Psoriasis

United States, Poland, Canada
Boehringer Ingelheim

Completed

Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

United States, Germany, Russian Federation, Czechia, Poland, Ukraine, Estonia, Slovakia
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)

Psoriasis
MetrioPharm AG
Parexel

Completed

Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients

Psoriasis | Plaque Psoriasis

Germany
Pfizer

Completed

A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

Belgium, Spain, Germany, France, Hungary, Russian Federation, Singapore, Argentina, Austria, Bosnia and Herzegovina, Bulgaria, Chile, Colombia, Croatia, Czechia, Denmark, Hong Kong, Israel, Korea, Republic of, Netherlands, Poland, Slovaki... and more
Pfizer

Completed

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

United States, Denmark, Slovakia, Canada, Australia, Argentina, Bulgaria, Netherlands, United Kingdom, Brazil, Finland, Greece
Novartis Pharmaceuticals

Completed

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Moderate to Severe Plaque-type Psoriasis

Germany, United States, Belgium, Colombia, Spain, Estonia, Hungary, Japan, Lithuania, Taiwan, Australia, Korea, Republic of, Canada, Singapore, Italy, Israel, Sweden, Guatemala, United Kingdom, Argentina, France, Poland, Latvia, Iceland, Finla... and more
AB Science

Completed

A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
Vitae Pharmaceuticals Inc., an Allergan affiliate

Completed

An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers

Psoriasis

United States
Janssen Research & Development, LLC

Completed

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

Psoriasis

United States, Canada, Poland
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis

Moderate-to-severe Plaque Psoriasis

China
Momenta Pharmaceuticals, Inc.

Completed

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

Psoriasis | Chronic Plaque Psoriasis

United States, Poland, Canada, Czechia, Estonia, Germany, Slovakia, Bulgaria, Latvia
Novartis Pharmaceuticals

Completed

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) (JUNCTURE)

Plaque-type Psoriasis

Germany, United States, France, Estonia, Canada
Wake Forest University

Completed

Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis

Psoriasis

United States
Novartis Pharmaceuticals

Completed

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks (FEATURE)

Moderate to Severe Plaque-type Psoriasis

Germany, United States, Estonia, France, Canada
Amgen
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis
Novartis Pharmaceuticals

Completed

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Moderate to Severe Chronic Plaque-Type Psoriasis

United States, Germany, Japan, Bulgaria, Czechia, Singapore, Switzerland, United Kingdom, Italy, France, Vietnam, Poland, Slovakia, Austria, Canada
Promius Pharma, LLC

Completed

DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis (HPA axis)

Psoriasis

United States
Promius Pharma, LLC

Completed

A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis

Psoriasis

United States
Promius Pharma, LLC

Completed

A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis

Chronic Stable Plaque Psoriasis

United States
Tianjin Ever Union Biotechnology Co., Ltd.

Unknown

Safety and Efficacy of UC-MSCs in Patients With Plaque Psoriasis

Moderate and Severe Plaque Psoriasis

China
Merck KGaA, Darmstadt, Germany

Completed

A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis | Candidates for Systemic Therapy for Psoriasis

Switzerland
Kang Stem Biotech Co., Ltd.

Unknown

Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis

Psoriasis

Korea, Republic of
Novartis Pharmaceuticals

Completed

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE)

Moderate to Severe Palmoplantar Psoriasis

Belgium, United States, Hungary, Russian Federation, Turkey, Australia, Israel, Netherlands, Portugal, Spain, United Kingdom, Norway, Slovakia, Canada, Finland

3

Subscribe